Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
F2RL1 Biologics Sequence Review Report 2026: Proteinase-activated receptor 2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
F2RL1 Biologics Sequence Review Report 2026: Proteinase-activated receptor 2 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of F2RL1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
FCGRT Biologics Sequence Review Report 2026: IgG receptor FcRn large subunit p51 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
FCGRT Biologics Sequence Review Report 2026: IgG receptor FcRn large subunit p51 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of FCGRT protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
F2R Biologics Sequence Review Report 2026: Proteinase-activated receptor 1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
F2R Biologics Sequence Review Report 2026: Proteinase-activated receptor 1 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of F2R protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
DRD3 Biologics Sequence Review Report 2026: D(3) dopamine receptor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
DRD3 Biologics Sequence Review Report 2026: D(3) dopamine receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of DRD3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
DRD5 Biologics Sequence Review Report 2026: D(1B) dopamine receptor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
DRD5 Biologics Sequence Review Report 2026: D(1B) dopamine receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of DRD5 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
DRD2 Biologics Sequence Review Report 2026: D(2) dopamine receptor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
DRD2 Biologics Sequence Review Report 2026: D(2) dopamine receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of DRD2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
DRD4 Biologics Sequence Review Report 2026: D(4) dopamine receptor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
DRD4 Biologics Sequence Review Report 2026: D(4) dopamine receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of DRD4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CRHR1 Biologics Sequence Review Report 2026: Corticotropin-releasing hormone receptor 1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CRHR1 Biologics Sequence Review Report 2026: Corticotropin-releasing hormone receptor 1 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of CRHR1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
DRD1 Biologics Sequence Review Report 2026: D(1A) dopamine receptor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
DRD1 Biologics Sequence Review Report 2026: D(1A) dopamine receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of DRD1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CNR2 Biologics Sequence Review Report 2026: Cannabinoid receptor 2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CNR2 Biologics Sequence Review Report 2026: Cannabinoid receptor 2 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of CNR2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CMKLR2 Biologics Sequence Review Report 2026: Chemerin-like receptor 2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CMKLR2 Biologics Sequence Review Report 2026: Chemerin-like receptor 2 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of CMKLR2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CHRNB4 Biologics Sequence Review Report 2026: Neuronal acetylcholine receptor subunit beta-4 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CHRNB4 Biologics Sequence Review Report 2026: Neuronal acetylcholine receptor subunit beta-4 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of CHRNB4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →